中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

33 records (took 0.016 seconds)

    Bicyclic Heterocylic Derivatives and Methods of Use
    31.
    发明申请
    Bicyclic Heterocylic Derivatives and Methods of Use 审中-公开
    双环异构衍生物和使用方法

    公开(公告)号：US20110130385A1

    公开(公告)日：2011-06-02

    申请号：US13054841

    申请日：2009-07-21

    Applicant: Manuel De Lera Ruiz ,  Michael Y. Berlin ,  Junying Zheng ,  Robert G. Aslanian ,  Kevin D. Mccormick

    Inventor： Manuel De Lera Ruiz ,  Michael Y. Berlin ,  Junying Zheng ,  Robert G. Aslanian ,  Kevin D. Mccormick

    IPC: A61K31/55 ,  C07D401/14 ,  A61K31/4725 ,  A61P11/00 ,  A61P9/00 ,  A61P29/00 ,  A61P1/00 ,  A61P3/00 ,  A61P25/00

    CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D413/14 ,  C07D417/14 ,  C07D487/04

    Abstract: The present invention relates to novel bicyclic heterocycle derivatives, pharmaceutical compositions comprising the bicyclic heterocycle derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is: I, Ia, Ib ou Ic. R2 is alkyl, alkenyl, aryl, cycloalkyl. heterocycloalkyl or heteroaryl, any of which can be optionally substituted with R3; Y is —C(O)—, —S—, —S(O)—, —S(O)2—, —CH2— or —O—, such that if Y is —O— or —S—, then M is other than N and R1 is (Ib);

    Abstract translation: 本发明涉及新的双环杂环衍生物，包含双环杂环衍生物的药物组合物和这些化合物用于治疗或预防过敏，过敏诱发的气道反应，充血，心血管疾病，炎性疾病，胃肠道疾病， 糖尿病，糖尿病并发症，葡萄糖耐量降低或空腹血糖受损。 R 1是：I，Ia，Ib o Ic。 R2是烷基，烯基，芳基，环烷基。 杂环烷基或杂芳基，其中任何一个可以任选被R 3取代; Y是-C（O） - ， - S - ， - S（O） - ， - S（O）2 - ， - CH 2 - 或-O-，如果Y是-O-或-S-， M不是N，R1是（Ib）;

    1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine
    33.
    发明申请
    1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine 失效
    1 - [[1 - [（2-氨基-6-甲基-4-吡啶基）甲基] -4-氟-4-哌啶基]羰基] -4- [2-（2-吡啶基）-3H-咪唑并[4 ，5-b]吡啶-3-基]哌啶

    公开(公告)号：US20070066644A1

    公开(公告)日：2007-03-22

    申请号：US11523489

    申请日：2006-09-19

    Applicant: Manuel de Lera Ruiz ,  Robert Aslanian ,  Michael Berlin ,  Kevin McCormick ,  Chander Celly

    Inventor： Manuel de Lera Ruiz ,  Robert Aslanian ,  Michael Berlin ,  Kevin McCormick ,  Chander Celly

    IPC: A61K31/4745 ,  C07D471/02

    CPC classification number: C07D471/04

    Abstract: The present invention discloses the compound of Formula I and pharmaceutically acceptable salts and solvates thereof. The invention also relates to pharmaceutical compositions comprising the Compound of Formula I and its use in treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease. The invention also relates to the use of a combination of the Compound of Formula I with additional therapeutic agents for treating obesity, metabolic syndrome, diabetes, hepatic lipidosis or nonalcoholic fatty liver disease.

    Abstract translation: 本发明公开了式I化合物及其药学上可接受的盐和溶剂化物。 本发明还涉及包含式I化合物及其在治疗肥胖，代谢综合征，糖尿病，肝脏脂质沉积或非酒精性脂肪性肝病中的用途的药物组合物。 本发明还涉及式I化合物与用于治疗肥胖，代谢综合征，糖尿病，肝脏脂质沉积或非酒精性脂肪性肝病的其它治疗剂的组合的用途。

Patent Agency Ranking